UnknownPhase 2NCT04221516

Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma

Studying Nasopharyngeal carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Nanfang Hospital, Southern Medical University
Principal Investigator
Jian Guan, Ph.D.
Nanfang Hospital, Southern Medical University
Intervention
Camrelizumab(drug)
Enrollment
52 target
Eligibility
18 years · All sexes
Timeline
20202024

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04221516 on ClinicalTrials.gov

Other trials for Nasopharyngeal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Nasopharyngeal carcinoma

← Back to all trials